Click the logo for more information

About Mavacamten (Trade name Camzyos):   Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy was developed by Myokardia and purchased by Bristol Myers Squibb.

Mavacamten aims to tackle HCM at its source rather than managing symptoms. Research is underway for other types of heart disease, including non-obstructive HCM and heart failure with preserved ejection fraction. Bristol Myers Squibb is also testing whether the drug can spare patients from surgical procedures. Mavacamten may reduce the number of people who need to go on to have SRT, achieved using surgery or a catheter-based procedure, which is a standard therapy for severe HCM.

mava1

The mechanism of action for mavacamten,  a cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy.

Source: https://www.dicardiology.com/content/mavacamten-effective-treating-obstructive-hypertrophic-cardiomyopathy

BMS provided links related to Camzyos: 

Online Information click here: CAMZYOS PATIENT PORTAL

Camzyos - Telephone support line for HCMA Members: 888-694-2059

The information line can provide answers to questions about access and the specific programs available through the MyCamzyos program.

 

CAMZYOS Medication Guide

CAMZYOS U.S. Prescribing Information

CAMZYOS REMS Program

 

Access:  Mavacamten, an orally administered, small-molecule modulator of cardiac myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic cardiomyopathy.  Echo-based titration will be required and the HCMA recommends evaluation by a recognized Center of Excellence in shared decision making regarding health care choices

Camzyos is only available through a restricted program called the Camzyos REMS Program because of the risk of heart failure due to systolic dysfunction. Notable requirements of the Camzyos REMS Program include the following:

Prescribers must be certified by enrolling in the REMS Program.
Patients must enroll in the REMS Program and comply with ongoing monitoring requirements.
Pharmacies must be certified by enrolling in the Camzyos REMS Program and must only dispense to patients who are authorized to receive Camzyos.

 

Medicare support information:

The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is pleased to announce that it has opened a new fund to assist individuals living with cardiomyopathy. Through the new fund, HealthWell will provide up to $10,000 in medication copayment or insurance premium assistance for a 12-month grant period to eligible Medicare patients who have annual household incomes up to 500 percent of the federal poverty level.

“For many living with cardiomyopathy, the ability to carry out normal daily functions can be compromised due to symptoms such as shortness of breath, swelling of the feet and legs, and fatigue,” said HealthWell Foundation President, Krista Zodet. “These symptoms, among others, can cause the patient undue stress, which can further exacerbate their condition. For cardiomyopathy patients who are on Medicare, the financial burden alone can attribute to stress and fatigue. We are honored that our donors understand these challenges and have provided HealthWell with the financial resources to assist Medicare patients who would otherwise forgo proper treatment of their condition due to cost.”

To determine eligibility and apply for financial assistance,

visit HealthWell’s Cardiomyopathy – Medicare Access Fund page.

Watch the special edition of our Bighearted Warrior Tour where we speak with members of the Camzyos™ team at Bristol Myers Squibb to better explain:
  • Label Indication
  • Patient Assistance Program
  • Medicare Access

Click below for more information on Medicare Part D:

My sincere thanks to all who have been a part of this important chapter of HCM history.  I end with a word of balance and cautious optimism. We will learn together the effectiveness, sustainability, and role of myosin inhibitors for the HCM community.  On your marks, get set, go – cautiously into the future together.  - Lisa Salberg

 

Read Lisa's full letter regarding the release of Camzyos here.

“Adding mavacamten to maximally tolerated medical therapy significantly reduced patients’ eligibility for and/or desire to proceed with septal reduction therapy,” says Dr. Desai, Director of the Hypertrophic Cardiomyopathy Center at Cleveland Clinic. “No approved medical therapies have been developed specifically for hypertrophic cardiomyopathy or evaluated in randomized controlled trials for this condition, so mavacamten shows promise to address an unmet need for a non-invasive treatment in this setting.”

Source: https://consultqd.clevelandclinic.org/mavacamten-significantly-reduces-patients-need-for-septal-reduction-therapy-over-16-weeks/

  • Rader F, Choudhury L, Saberi S, et al. Updated cumulative results of treatment with mavacamten from the EXPLORER-LTE cohort of the MAVA-LTE study in patients with obstructive hypertrophic cardiomyopathy. Presented at: ACC 2022. April 3, 2022. Washington, DC.
  • Hegde SM, Lester SJ, Solomon SD, Michels M, Elliott PM, Nagueh SF, Choudhury L, Zemanek D, Zwas DR, Jacoby D, Wang A, Ho CY, Li W, Sehnert AJ, Olivotto I, Abraham TP. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532. doi: 10.1016/j.jacc.2021.09.1381.
  • Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.
  • J Med Econ. 2022 Jan-Dec;25(1):51-58. doi: 10.1080/13696998.2021.2011301.
    Burstein Waldman C, Owens A. A plain-language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy. Future Cardiol. 2021 Oct;17(7):1269-1275. doi: 10.2217/fca-2021-0044. Epub 2021 May 21.
  • Spertus JA, Fine JT, Elliott P, Ho CY, Olivotto I, Saberi S, Li W, Dolan C, Reaney M, Sehnert AJ, Jacoby D. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021 Jun 26;397(10293):2467-2475. doi: 10.1016/S0140-6736(21)00763-7. Epub 2021 May 15.
  • Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29. Erratum in: Lancet. 2020 Sep 12;396(10253):758.Ho CY, Olivotto I, Jacoby D, Lester SJ, Roe M, Wang A, Waldman CB, Zhang D, Sehnert AJ, Heitner SB. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy. Circ Heart Fail. 2020 Jun;13(6):e006853. doi: 10.1161/CIRCHEARTFAILURE.120.006853. Epub 2020 Jun 5.